Although a limitation of this work is that the LysM transgene is also expressed in myeloid-derived cells in addition to DCs (such as macrophages), which could affect the observed phenotype, it is compelling to find the preserved phenotype in tumor-derived DCs (TIDCs) purified from mutant tumors. The use of this model may be considered in light of other transgenic Cre models that are used to target the myeloid compartment (e.g., CD11c Cre). The latter may also have some limitations, as CD11c is also expressed on macrophages [54] and mature mouse DCs downregulate their expression of CD11c [55].